Special Issue

Innovative Strategies in Overcoming Antimicrobial Resistance: From Phage Therapy to Combination

Message from the Guest Editor

Bacteriophages (phages) are viruses that infect, replicate within, and kill bacteria, offering immense potential as a powerful tool in combating antibiotic resistance. There is renewed interest in phage therapy as many bacterial infections are becoming resistant to antibiotics, leaving us with fewer effective treatment options. The killing mechanism of phages differs from that of antibiotics and holds great promise not only in treating infections but also in preventing their spread and minimizing the emergence of antibiotic resistance. In the following Special Issue "Innovative Strategies in Overcoming Antimicrobial Resistance: From Phage Therapy to Combination", we invite your original cutting-edge research (research articles and reviews) that have the potential to contribute to our understanding of phage therapy. The topics covered in this Special Issue include, but are not limited to, the following:

- Novel phage discovery
- Basic phage therapy
- Phage engineering
- Phage +/- antibiotic therapy
- Phage pharmacokinetics

Guest Editor

Dr. Rajnikant Sharma
USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA

Deadline for manuscript submissions

20 July 2026

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/246505

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

mdpi.com/journal/cimb

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/cimb

MDPI

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia
Department of Pathology and Molecular Medicine, University of Otago, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.